Table 2.
Group | MDA | SOD | CAT | GSH |
---|---|---|---|---|
(nmol/g tissue) | (UI/mg tissue) | (UI/mg tissue) | (mg/g tissue) | |
I | 0.47 ± 0.04c | 0.35 ± 0.02a | 0.40 ± 0.02a.b | 29.74 ± 1.98b |
II | 1.49 ± 0.18a | 0.15 ± 0.01d | 0.13 ± 0.02d | 15.84 ± 1.30c |
III | 0.66 ± 0.03b | 0.31 ± 0.02b.c | 0.36 ± 0.02c | 32.58 ± 2.68a.b |
IV | 0.60 ± 0.04b.c | 0.28 ± 0.03c | 0.43 ± 0.02a | 33.01 ± 2.26a |
V | 0.64 ± 0.03b | 0.33 ± 0.02a.b | 0.37 ± 0.03b.c | 29.93 ± 0.90b |
MDA: malondialdehyde; SOD: superoxide dismutase; CAT: catalase; GSH: reduced glutathione.
I: control group; II: CCl4 induced hepatotoxicity group; III: Silymarin treated group; IV and V: Tamarindus indica L. tablets treated groups at doses 100 mg/kg and 200 mg/kg, respectively.
Data are expressed as mean ± SD (n = 7).
Different letters on columns indicate significant statistical differences (p < 0.05).